A global coalition of health advocates is intensifying its campaign against pharmaceutical giant Gilead Sciences. They demand equitable access to its revolutionary long-acting injectable HIV prevention drug, lenacapavir. Activists are calling for a universal generic price of $40 per person per year for all low and middle-income countries. They warn that Gilead’s current policies entrench life-threatening inequities in the global…
Tag: pharmaceuticals
-
Generic HIV Prevention Drug to Cost Just $40 Annually from 2027
In a monumental step forward for global public health, Indian pharmaceutical companies Dr Reddy’s Laboratories and Hetero Labs have announced they will produce and sell generic versions of a revolutionary HIV prevention drug. It will be available for around $40 per year. Availability is expected from 2027. The drug, lenacapavir, is a long-acting injectable developed by Gilead Sciences. It has…
-
Ascendis to Delist from the Johannesburg Stock Exchange
Health group Ascendis Health plans a significant change. The company will delist from the Johannesburg Stock Exchange (JSE). It has made a conditional offer to its investors. Ascendis will repurchase shares from them. The market reacted very positively to this news. The company’s stock price surged by 13.4%. This move to delist Ascendis is a key part of its new strategy. The…
-
Cheaper Weight-Loss Drugs for Global Health Needs
\n\nThe decision directly affects the popular GLP-1 agonist drugs, including the active ingredients in brands like Ozempic, Wegovy, and Mounjaro. \n\n\n\nThe WHO’s recommendation aims to pressure pharmaceutical giants to lower prices and encourage the production of affordable generic versions. This is particularly important for people in developing countries, where they are needed most.\n\n\n\nThis move underscores the severity of the global…
-
Gilead’s Lenacapavir to Reach High-Burden Nations ‘At Cost’
The US government and Gilead Sciences have announced a landmark plan to supply the long-acting HIV prevention drug, lenacapavir, at cost to high-burden countries. This initiative aims to protect 2 million people via PEPFAR and The Global Fund. In a major step forward for global public health, the United States State Department announced a groundbreaking plan on Thursday. The aim…
-
Aspen Unlocking Value with New Manufacturing Strategies
Aspen Pharmacare’s CEO, Stephen Saad, has declared that all hands are on deck to overhaul the group’s manufacturing business. He identified the performance of its sterile unit as a significant drag on earnings. This underperformance has caused the market to undervalue the company. This move is part of Aspen’s effort to unlock value for its stakeholders and enhance its market…
-
Global Health Crisis and the Threat to NTD Programmes
Millions of life-saving medicines used to combat debilitating neglected tropical diseases (NTDs) are at risk of being wasted. Stockpiles are expiring in warehouses following the abrupt termination of a major US aid programme. Global health experts have sounded the alarm. They warn that this funding crisis could sabotage years of hard-won progress. Moreover, it could lead to a resurgence of…
-
Adcock Ingram Reports Flat Profit Despite Winter Surge
Pharmaceutical giant Adcock Ingram has announced flat annual profits despite a significant recovery in the second half of its financial year. This was buoyed by strong demand for its popular over-the-counter winter medicines. In a landmark move, the maker of household staples like Panado and Corenza-C is also set to delist from the Johannesburg Stock Exchange (JSE). This follows a…
-
Novo Nordisk Hiring Freeze After Wegovy Sales Decline
Danish pharmaceutical giant Novo Nordisk, which rode a wave of unprecedented success with its weight-loss drug Wegovy, has announced a global hiring freeze for non-critical roles. This signals a dramatic shift from rapid expansion to rigorous cost-cutting. Sales begin to slow and competition intensifies. Novo Nordisk’s hiring freeze is a significant turn for the company. The Wegovy Hiring Spree The…
-
Regulatory Delays Threaten Africa’s Pharmaceutical Ambition
Critical delays in aligning Africa’s pharmaceutical regulations with World Health Organisation (WHO) standards are jeopardising the continent’s R1.25-trillion ($70bn) goal. They aim to become a self-sufficient pharmaceuticals manufacturing hub, according to a top industry executive. Stavros Nicolaou, a senior executive at Aspen Pharmacare and chair of Pharmaceuticals Made in South Africa (Pharmisa), warned that this regulatory bottleneck is preventing African…
-
Vertex’s Trikafta: Addressing Drug Pricing Issues
Health activists are demanding that the Competition Commission reopen its investigation into pharmaceutical giant Vertex. They argue the company’s pricing and access strategies for its revolutionary cystic fibrosis drug, Trikafta, have created a deep and unjust divide. As a result, the treatment is out of reach for most South African patients. The commission dropped its initial probe into Vertex in…